Leader in developing recombinant antibody mixtures

Symphogen is expanding its pipeline of innovative next generation antibody therapeutics of recombinant antibody mixtures for the treatment of cancer, while pursuing application of its technology in infectious disease through strategic partnerships. The vast majority of programs in the pipeline are multi-targeting mAb mixtures, uniquely well-suited to improve efficacy and to address drug resistance, a major therapeutic challenge in cancer as well as in infectious disease.

Symphogen's pipeline is fueled by its productive technology suite capable of identifying, selecting, manufacturing and characterizing optimal antibody mixtures.



mAb Mixtures and Cancer